Blood test may forecast breast cancer drug response before surgery
NCT ID NCT01834950
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This study is testing whether certain markers in the blood can predict how well the drug trastuzumab shrinks tumors in women with early HER2-positive breast cancer. Participants receive trastuzumab before breast-conserving surgery, and researchers compare blood marker levels with tumor response. The goal is to find early signs of response or resistance, which could help tailor treatment in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Blood test to identify biomarkers
- What this could lead to
- If successful, this could help doctors predict early on whether trastuzumab will shrink a tumor, potentially guiding more personalized treatment decisions.
- What could go wrong
- This is a small, early exploratory study. The biomarkers may not reliably predict response, and findings may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNTREATED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2(HER2)POSITIVE EARLY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Gustave Roussy
Villejuif, Val de Marne, 94805, France